1.35亿美元！与默沙东“分手”后，这家NK细胞疗法公司再冲IPO

医药魔方Pro07-16

7月15日，Artiva Biotherapeutics更新了IPO计划，宣布将以每股14-16美元的价格，出售870万股，预计获得1.168亿美元的净收益。此外，如果承销商以15美元的价格购买130万股的30天期权，则净收入将增至1.35亿美元。来源：Artiva招股书Artiva表示，将把所筹资金用于支持其同种异体NK细胞疗法AlloNK的开发，该药物可用于治疗系统性红斑狼疮（SLE），目前...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2451933439?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-16 19:15","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2451933439","market":"us","top_or_hot":-1,"title":"1.35亿美元！与默沙东“分手”后，这家NK细胞疗法公司再冲IPO","media":"医药魔方Pro","content":"<div>\n<p>7月15日，Artiva Biotherapeutics更新了IPO计划，宣布将以每股14-16美元的价格，出售870万股，预计获得1.168亿美元的净收益。此外，如果承销商以15美元的价格购买130万股的30天期权，则净收入将增至1.35亿美元。来源：Artiva招股书Artiva表示，将把所筹资金用于支持其同种异体NK细胞疗法AlloNK的开发，该药物可用于治疗系统性红斑狼疮（SLE），目前...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407161936389f55d586&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1.35亿美元！与默沙东“分手”后，这家NK细胞疗法公司再冲IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1.35亿美元！与默沙东“分手”后，这家NK细胞疗法公司再冲IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-16 19:15 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407161936389f55d586&s=b><strong>医药魔方Pro</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月15日，Artiva Biotherapeutics更新了IPO计划，宣布将以每股14-16美元的价格，出售870万股，预计获得1.168亿美元的净收益。此外，如果承销商以15美元的价格购买130万股的30天期权，则净收入将增至1.35亿美元。来源：Artiva招股书Artiva表示，将把所筹资金用于支持其同种异体NK细胞疗法AlloNK的开发，该药物可用于治疗系统性红斑狼疮（SLE），目前...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407161936389f55d586&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1934455194.USD","symbol_name":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407161936389f55d586&s=b","article_id":"2451933439","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407161936389f55d586&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2451933439","pubTimestamp":1721128521,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"同样是在2021年，默沙东与Artiva签订了总额超18亿美元的全球独家合作和许可协议，前者将利用后者的现货型同种异体NK细胞制造平台及专有的CAR-NK技术开发针对实体瘤相关抗原的新型CAR-NK细胞疗法。而根据Artiva近期一份公开文件显示，与默沙东的合作已经于2023年10月结束。与默沙东的合作破灭之后，Artiva近日宣布将寻求在美股上市，以支持核心管线AlloNK的临床开发。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","BK4534":"瑞士信贷持仓","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","MRK":"默沙东","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","BK4559":"巴菲特持仓","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4588":"碎股","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU1917777945.USD":"安联专题基金Cl AT Acc","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC"},"translate_title":"$135 million! After \"breaking up\" with Merck, the NK cell therapy company rushed to IPO again","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1},"content_text":"7月15日，Artiva Biotherapeutics更新了IPO计划，宣布将以每股14-16美元的价格，出售870万股，预计获得1.168亿美元的净收益。此外，如果承销商以15美元的价格购买130万股的30天期权，则净收入将增至1.35亿美元。来源：Artiva招股书Artiva表示，将把所筹资金用于支持其同种异体NK细胞疗法AlloNK的开发，该药物可用于治疗系统性红斑狼疮（SLE），目前正在进行临床I期试验。系统性红斑狼疮是一种自身免疫疾病，特征是B细胞功能异常，可导致器官损伤并增加死亡风险。AlloNK疗法还在被用于其他自身免疫疾病的治疗，包括类风湿性关节炎和天疱疮（一种导致皮肤起泡的罕见疾病）。Artiva整体管线（来源：Artiva招股书）其实早在2021年，成立仅2年的Artiva就曾经递交过IPO申请，但18个月后，Artiva撤回了IPO。同样是在2021年，默沙东与Artiva签订了总额超18亿美元的全球独家合作和许可协议，前者将利用后者的现货型同种异体NK细胞制造平台及专有的CAR-NK技术开发针对实体瘤相关抗原的新型CAR-NK细胞疗法。而根据Artiva近期一份公开文件显示，与默沙东的合作已经于2023年10月结束。与默沙东的合作破灭之后，Artiva近日宣布将寻求在美股上市，以支持核心管线AlloNK的临床开发。根据招股书，Artiva2023年全年的研发费用为5000万美元，2024年第一季度的研发费用约为1100万美元，而截至今年3月底，Artiva拥有的现金、现金等价物以及短期投资约为6200万美元，在资金方面，Artiva显然已经捉襟见肘。既没有商业化的产品能够实现自我回血，且与默沙东的大金额合作已经告吹，Artiva在此刻寻求上市，无疑是自救之举。参考资料：https://www.fiercebiotech.com/biotech/artiva-sets-out-135m-ipo-plans-push-nk-cell-therapy-through-trialsCopyright © 2024 PHARMCUBE. All Rights Reserved.欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2451933439"}